论文部分内容阅读
[目的]观察异环磷酰胺(IFO)为主的方案治疗晚期非小细胞肺癌的疗效和毒副反应。[方法]采用IAP或IEP方案治疗晚期非小细胞肺癌38例 ,IFO1 4g/m2d1～5;DDP25mg/m2d1～3;ADM30mg/m2d 1 或Vp1660mg/m2d1～3。[结果]鳞癌有效率35 7 %(5/14) ;腺癌有效率为45.0%(9/20) ;总有效率39 5%(15/38)。主要毒副反应为骨髓抑制 ,发生率为39 5 %。[结论]IFO联合化疗方案治疗晚期非小细胞肺癌有效率较高 ,毒副反应可以耐受 ,值得临床进一步推广。
[Objective] To observe the efficacy and side effects of ifosfamide (IFO)-based regimen in the treatment of advanced non-small cell lung cancer. [Methods] 38 cases of advanced non-small cell lung cancer were treated with IAP or IEP regimen, IFO1 4g/m2d1~5, DDP25mg/m2d1~3, ADM30mg/m2d 1 or Vp1660mg/m2d1~3. [Results] The effective rate of squamous cell carcinoma was 35.7 % (5/14); the effective rate of adenocarcinoma was 45.0% (9/20); the total effective rate was 39 5% (15/38). The main toxicity was myelosuppression, with an incidence of 39.5%. [Conclusion] The combined use of IFO and chemotherapy in the treatment of advanced non-small cell lung cancer is effective and toxic and side effects can be tolerated. It is worth further promotion in clinic.